Lantern Pharma is trading 8.75% down at $2.40 after its August 14, 2026, second-quarter results showed a $7.1 million net loss, or $0.57 per share, versus analyst expectations of a $0.38 loss.
- Operating loss improved 25% year over year.
- Declining liquidity, additional financing needs, and potential dilution appear to have outweighed positive HARMONIC trial data and the Open Medicine AI spinoff.